What is Replicate Bioscience?
Replicate Bioscience is at the forefront of developing innovative self-replicating RNA (srRNA) technology aimed at expanding treatment options for various diseases. Their platform utilizes srRNA vectors to enhance protein expression and therapeutic effects within cells. The company is advancing a diverse pipeline of srRNA treatments targeting infectious diseases, oncology, and autoimmune disorders. By improving upon traditional linear mRNA, Replicate aims to provide better outcomes for a larger patient population. This focus positions them as a key player in the next generation of genetic medicine.
How much funding has Replicate Bioscience raised?
Replicate Bioscience has raised a total of $46M across 2 funding rounds:
Angel/Seed
$6M
Series A
$40M
Angel/Seed (2021): $6M with participation from Apple Tree Partners
Series A (2021): $40M led by ATP
Key Investors in Replicate Bioscience
Apple Tree Partners
Apple Tree Partners operates ATP RD Labs, an incubator and accelerator focused on foundational science for its portfolio companies. They offer comprehensive services including compound screening and preclinical pharmacology to discover and evaluate small molecules.
ATP
ATP is a significant investor in Replicate Bioscience, contributing to the company's strategic growth and development in the biotechnology sector.
Undisclosed Investor
An undisclosed investor participated in the funding round, indicating broad support for Replicate Bioscience's innovative srRNA technology.
What's next for Replicate Bioscience?
With the recent infusion of capital, Replicate Bioscience is poised for significant growth and pipeline advancement. The major strategic investment suggests strong investor confidence in their srRNA technology and its therapeutic potential across multiple disease areas. This backing will likely fuel further research and development, clinical trial progression, and potential expansion into new therapeutic indications. The company's trajectory indicates a move towards scaling its operations and solidifying its market position in the competitive biotech landscape.
See full Replicate Bioscience company page
